Which has better valuation and earnings, VCYT or INNV?

Veracyte has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.30 $66.35M $1.09 43.42 InnovAge $853.70M 1.45 -$30.31M -$0.09 N/A

Is VCYT or INNV more profitable?

Veracyte has a net margin of 16.25% compared to InnovAge's net margin of -1.22%. Veracyte's return on equity of 9.07% beat InnovAge's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% InnovAge -1.22% -4.73% -2.20%

Does the media favor VCYT or INNV?

In the previous week, Veracyte had 4 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for Veracyte and 2 mentions for InnovAge. Veracyte's average media sentiment score of 1.14 beat InnovAge's score of 0.93 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INNV or CON?

In the previous week, Concentra Group Holdings Parent had 3 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for Concentra Group Holdings Parent and 2 mentions for InnovAge. Concentra Group Holdings Parent's average media sentiment score of 1.08 beat InnovAge's score of 0.93 indicating that Concentra Group Holdings Parent is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Concentra Group Holdings Parent 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OPCH or INNV?

In the previous week, Option Care Health had 4 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for Option Care Health and 2 mentions for InnovAge. Option Care Health's average media sentiment score of 1.46 beat InnovAge's score of 0.93 indicating that Option Care Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Option Care Health 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INNV or LFST?

In the previous week, LifeStance Health Group had 2 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for LifeStance Health Group and 2 mentions for InnovAge. InnovAge's average media sentiment score of 0.93 beat LifeStance Health Group's score of 0.88 indicating that InnovAge is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LifeStance Health Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INNV or PRVA?

In the previous week, Privia Health Group had 2 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Privia Health Group and 2 mentions for InnovAge. Privia Health Group's average media sentiment score of 1.77 beat InnovAge's score of 0.93 indicating that Privia Health Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Privia Health Group 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

InnovAge (INNV) Competitors

$9.11 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$8.90 -0.21 (-2.31%)

As of 06/12/2026 07:55 PM Eastern

Compare

INNV vs. VCYT, CON, OPCH, LFST, and PRVA

Should you buy InnovAge stock or one of its competitors? MarketBeat compares InnovAge with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InnovAge include Veracyte (VCYT), Concentra Group Holdings Parent (CON), Option Care Health (OPCH), LifeStance Health Group (LFST), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.

How does InnovAge compare to Veracyte?

Veracyte (NASDAQ:VCYT) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Veracyte presently has a consensus price target of $47.57, suggesting a potential upside of 0.51%. InnovAge has a consensus price target of $7.00, suggesting a potential downside of 23.16%. Given Veracyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Veracyte is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Veracyte has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Veracyte has higher earnings, but lower revenue than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.30	$66.35M	$1.09	43.42
InnovAge	$853.70M	1.45	-$30.31M	-$0.09	N/A

Veracyte has a net margin of 16.25% compared to InnovAge's net margin of -1.22%. Veracyte's return on equity of 9.07% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
InnovAge	-1.22%	-4.73%	-2.20%

In the previous week, Veracyte had 4 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for Veracyte and 2 mentions for InnovAge. Veracyte's average media sentiment score of 1.14 beat InnovAge's score of 0.93 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.3% of InnovAge shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Comparatively, 1.0% of InnovAge shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Veracyte beats InnovAge on 15 of the 17 factors compared between the two stocks.

How does InnovAge compare to Concentra Group Holdings Parent?

InnovAge (NASDAQ:INNV) and Concentra Group Holdings Parent (NYSE:CON) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

InnovAge currently has a consensus target price of $7.00, indicating a potential downside of 23.16%. Concentra Group Holdings Parent has a consensus target price of $30.20, indicating a potential upside of 7.32%. Given Concentra Group Holdings Parent's stronger consensus rating and higher probable upside, analysts clearly believe Concentra Group Holdings Parent is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Concentra Group Holdings Parent	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

InnovAge has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Concentra Group Holdings Parent has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

12.3% of InnovAge shares are owned by institutional investors. 1.0% of InnovAge shares are owned by insiders. Comparatively, 8.1% of Concentra Group Holdings Parent shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Concentra Group Holdings Parent has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Concentra Group Holdings Parent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.45	-$30.31M	-$0.09	N/A
Concentra Group Holdings Parent	$2.16B	1.66	$166.41M	$1.39	20.24

Concentra Group Holdings Parent has a net margin of 7.97% compared to InnovAge's net margin of -1.22%. Concentra Group Holdings Parent's return on equity of 47.14% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Concentra Group Holdings Parent	7.97%	47.14%	6.48%

In the previous week, Concentra Group Holdings Parent had 3 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for Concentra Group Holdings Parent and 2 mentions for InnovAge. Concentra Group Holdings Parent's average media sentiment score of 1.08 beat InnovAge's score of 0.93 indicating that Concentra Group Holdings Parent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Concentra Group Holdings Parent	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Concentra Group Holdings Parent beats InnovAge on 15 of the 16 factors compared between the two stocks.

How does InnovAge compare to Option Care Health?

Option Care Health (NASDAQ:OPCH) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Option Care Health presently has a consensus price target of $30.54, suggesting a potential upside of 47.10%. InnovAge has a consensus price target of $7.00, suggesting a potential downside of 23.16%. Given Option Care Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Option Care Health is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Option Care Health	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.64
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Option Care Health has a net margin of 3.64% compared to InnovAge's net margin of -1.22%. Option Care Health's return on equity of 18.17% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Option Care Health	3.64%	18.17%	7.16%
InnovAge	-1.22%	-4.73%	-2.20%

In the previous week, Option Care Health had 4 more articles in the media than InnovAge. MarketBeat recorded 6 mentions for Option Care Health and 2 mentions for InnovAge. Option Care Health's average media sentiment score of 1.46 beat InnovAge's score of 0.93 indicating that Option Care Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Option Care Health	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Option Care Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Option Care Health	$5.65B	0.58	$207.59M	$1.29	16.09
InnovAge	$853.70M	1.45	-$30.31M	-$0.09	N/A

98.1% of Option Care Health shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 1.7% of Option Care Health shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Option Care Health has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, InnovAge has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

Option Care Health beats InnovAge on 16 of the 17 factors compared between the two stocks.

How does InnovAge compare to LifeStance Health Group?

InnovAge (NASDAQ:INNV) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

InnovAge has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

InnovAge presently has a consensus price target of $7.00, suggesting a potential downside of 23.16%. LifeStance Health Group has a consensus price target of $9.75, suggesting a potential upside of 14.71%. Given LifeStance Health Group's stronger consensus rating and higher possible upside, analysts clearly believe LifeStance Health Group is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
LifeStance Health Group	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

LifeStance Health Group has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.45	-$30.31M	-$0.09	N/A
LifeStance Health Group	$1.49B	2.21	$9.66M	$0.06	141.67

12.3% of InnovAge shares are held by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Comparatively, 3.2% of LifeStance Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, LifeStance Health Group had 2 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for LifeStance Health Group and 2 mentions for InnovAge. InnovAge's average media sentiment score of 0.93 beat LifeStance Health Group's score of 0.88 indicating that InnovAge is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeStance Health Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group has a net margin of 1.55% compared to InnovAge's net margin of -1.22%. LifeStance Health Group's return on equity of 1.56% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
LifeStance Health Group	1.55%	1.56%	1.07%

Summary

LifeStance Health Group beats InnovAge on 16 of the 17 factors compared between the two stocks.

How does InnovAge compare to Privia Health Group?

InnovAge (NASDAQ:INNV) and Privia Health Group (NASDAQ:PRVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

12.3% of InnovAge shares are held by institutional investors. Comparatively, 94.5% of Privia Health Group shares are held by institutional investors. 1.0% of InnovAge shares are held by insiders. Comparatively, 5.7% of Privia Health Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InnovAge currently has a consensus target price of $7.00, suggesting a potential downside of 23.16%. Privia Health Group has a consensus target price of $31.15, suggesting a potential upside of 32.97%. Given Privia Health Group's stronger consensus rating and higher possible upside, analysts plainly believe Privia Health Group is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Privia Health Group has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.45	-$30.31M	-$0.09	N/A
Privia Health Group	$2.12B	1.39	$22.92M	$0.16	146.44

InnovAge has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market. Comparatively, Privia Health Group has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, Privia Health Group had 2 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Privia Health Group and 2 mentions for InnovAge. Privia Health Group's average media sentiment score of 1.77 beat InnovAge's score of 0.93 indicating that Privia Health Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Privia Health Group	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Privia Health Group has a net margin of 0.97% compared to InnovAge's net margin of -1.22%. Privia Health Group's return on equity of 2.81% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Privia Health Group	0.97%	2.81%	1.61%

Summary

Privia Health Group beats InnovAge on 15 of the 16 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INNV vs. The Competition

Export

Metric	InnovAge	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.24B	$8.90B	$6.52B	$12.05B
Dividend Yield	N/A	1.71%	2.67%	5.66%
P/E Ratio	-101.22	24.23	24.00	24.42
Price / Sales	1.45	23.91	533.77	123.88
Price / Cash	N/A	13.73	27.48	37.92
Price / Book	5.18	5.53	10.55	6.82
Net Income	-$30.31M	$177.22M	$3.57B	$337.56M
7 Day Performance	23.61%	1.54%	0.59%	1.16%
1 Month Performance	27.95%	10.04%	1.55%	3.16%
1 Year Performance	157.34%	5.88%	25.41%	30.60%

InnovAge Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INNV InnovAge	1.0745 of 5 stars	$9.11 flat	$7.00 -23.2%	+157.3%	$1.24B	$853.70M	N/A	2,440
VCYT Veracyte	2.3519 of 5 stars	$49.24 +4.2%	$47.57 -3.4%	+79.0%	$3.93B	$517.15M	45.17	790
CON Concentra Group Holdings Parent	3.956 of 5 stars	$26.08 +2.4%	$30.20 +15.8%	+31.4%	$3.34B	$2.16B	18.76	13,133	News Coverage Positive News Gap Down
OPCH Option Care Health	4.9264 of 5 stars	$21.11 +5.1%	$30.54 +44.7%	-34.3%	$3.31B	$5.65B	16.36	8,266	Positive News
LFST LifeStance Health Group	4.3867 of 5 stars	$7.66 +4.4%	$9.75 +27.3%	+61.6%	$2.97B	$1.49B	127.67	10,961	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INNV) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InnovAge (INNV) Competitors

INNV vs. VCYT, CON, OPCH, LFST, and PRVA

How does InnovAge compare to Veracyte?

Summary

How does InnovAge compare to Concentra Group Holdings Parent?

Summary

How does InnovAge compare to Option Care Health?

Summary

How does InnovAge compare to LifeStance Health Group?

Summary

How does InnovAge compare to Privia Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InnovAge (INNV) Competitors

INNV vs. VCYT, CON, OPCH, LFST, and PRVA

How does InnovAge compare to Veracyte?

Do analysts rate VCYT or INNV?

Which has more volatility and risk, VCYT or INNV?

Which has better valuation and earnings, VCYT or INNV?

Is VCYT or INNV more profitable?

Does the media favor VCYT or INNV?

Do insiders and institutionals have more ownership in VCYT or INNV?

Summary

How does InnovAge compare to Concentra Group Holdings Parent?

Do analysts prefer INNV or CON?

Which has more volatility and risk, INNV or CON?

Do insiders & institutionals believe in INNV or CON?

Which has stronger valuation & earnings, INNV or CON?

Is INNV or CON more profitable?

Does the media refer more to INNV or CON?

Summary

How does InnovAge compare to Option Care Health?

Do analysts recommend OPCH or INNV?

Is OPCH or INNV more profitable?

Does the media prefer OPCH or INNV?

Which has higher valuation and earnings, OPCH or INNV?

Do insiders and institutionals hold more shares of OPCH or INNV?

Which has more volatility and risk, OPCH or INNV?

Summary

How does InnovAge compare to LifeStance Health Group?

Which has more risk & volatility, INNV or LFST?

Do analysts recommend INNV or LFST?

Which has higher earnings & valuation, INNV or LFST?

Do insiders & institutionals have more ownership in INNV or LFST?

Does the media refer more to INNV or LFST?

Is INNV or LFST more profitable?

Summary

How does InnovAge compare to Privia Health Group?

Do insiders and institutionals have more ownership in INNV or PRVA?

Do analysts recommend INNV or PRVA?

Which has preferable valuation & earnings, INNV or PRVA?

Which has more risk and volatility, INNV or PRVA?

Does the media refer more to INNV or PRVA?

Is INNV or PRVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools